Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens

Table 3 Effect of albendazole treatment on antibody levels against GMZ2 and constituent in Na/Pf co-infected individuals

Vaccine antigens	Pretreatment (n = 57) (Median [IQR])	Post treatment (n = 57) (Median [IQR])	P-value
GMZ2
IgG1	38.2(10.2,90.6)	30.0(11.2,66.8)	0.002
IgG3	34.6(4.5, 142.0)	28.3(2.7121.3)	0.041
IgM	192.5(137.3326.2)	212.6(106.9400.0)	0.403
GLURP R0
IgG1	8.5(2.6,29.0)	8.2(0.9,24.3)	0.647
IgG3	14.3(2.0,45.4)	13.6(3.00,30.6)	0.024
IgM	155.8(88.8375.1)	139.5(81.2, 385.8)	0.184
MSP3
IgG1	56.2(28.5143.8)	41.7(28.0,52.7)	< 0.001
IgG3	44.9(8.3167.2)	50.1(23.9, 128.2)	0.130
IgM	332.8(269.2452.8)	36.3(10.6149.2)	< 0.001

Values are median (quartile). P-values were calculated using the Wilcoxon Signed Ranks Test
This analysis was done for those with hookworm and malaria parasites co-infection; pre-treatment (n = 57) and post-treatment (n = 57). Six individuals were lost during the post-treatment follow up
Abbreviations: LQ Lower Quartile, UQ Upper Quartile

ISSN: 1471-2334